Company intelligence / Profile preview

Trueline Therapeutics

Cambridge, Massachusetts, United Statesir.vorbio.com ↗

Ownership: Private
Development stage: Other

Overview

Trueline Therapeutics has completed IND-enabling studies for its lead MCL1 inhibitor TTX‑810, a macrocyclic small molecule designed for rapid clearance and high potency in treating solid and hematologic tumors. The company is preparing to initiate clinical development. Additional pipeline assets include a bispecific T-cell engager targeting CD3 x CD33 in Phase 1 for myelodysplastic syndromes and other preclinical/discontinued programs.

Therapeutic areas: OncologyHematology
Modalities: Small moleculeBispecific T-cell engager (BiTE)Macrocyclic compound
Industry: Biotech

Drug pipeline

2 assets

ANJ810

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Broad Institute of Harvard/MIT

Beyond the preview

Go deeper on Trueline Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trueline Therapeutics.

Explore the full profile